Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs). Immunosuppressive medication is the main therapeutic approach to reducing inflammation of the gastrointestinal tract. Immunocompromised patients are more vulnerable to severe courses of illness after infection wit...
Guardado en:
Autores principales: | Phil-Robin Tepasse, Richard Vollenberg, Tobias Max Nowacki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/974d936acac9461db59ea627ff5daff4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
por: Laura A. Lucaciu, et al.
Publicado: (2021) -
Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases
por: Lidiya V. Boldyreva, et al.
Publicado: (2021) -
Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran.
por: John F.Mayberry
Publicado: (2013) -
The Correlation Between MYO9B Gene Polymorphism and Inflammatory Bowel Disease in the Guangxi Zhuang Population
por: Zeng RZ, et al.
Publicado: (2021) -
Frequency of Oral Manifestation in Patients with Inflammatory Bowel Disease in Chile
por: Oviedo,C, et al.
Publicado: (2017)